ANIX is on breakout watch early today. Here's why.

StockWireNews

(Nasdaq: ANIX) Hits The Ground Running On Breaking News + Key Triggered Technicals (Major Green Surge)

January 16th

Greetings Readers,

ANIX is on breakout watch early today. Here's why.

With a hot green start to the day, ANIX continues to display a multitude of bullish technical indicators over at Barchart.

In fact, with 11 total triggered (including the website's "Trend Seeker" composite indicator), ANIX could be on the verge of an explosive move after climbing nearly $2.00 from November lows.

And with a 52-week high over $6.00, there could be a significant amount of room to move as ANIX trades above key potential support levels in its:

  • 50-Day Simple Moving Average (SMA)
  • 200-Day SMA
  • 13-Day Exponential Moving Average (EMA)

With breaking news out this morning, it may just be a matter of time until breakout buzz swirls around this Nasdaq profile.

Take a moment to review my report now and get ANIX on your screen quickly.

-----

*Anixa Biosciences, Inc. (ANIX)*

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.

Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology.

The company's treatment portfolio includes a novel treatment being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a treatment to prevent ovarian cancer.

And based on these glaring potential catalysts, ANIX could be set to take the breakout stage. Check them out:

#1. Bullish Technical Indicators (At Least 10 Triggered This Moment).

#2. Game-Changing News Comes In The Form Of Positive Phase 1 Study Data.

#3. Analyst Targets Suggest Triple-Digit Upside Potential From Current Levels.

But more on those in a second...

Anixa Snapshot

Clinical-stage company developing first-in-class products to treat & prevent cancer.
image

Anixa Biosciences, Inc. is developing therapies and treatments that are focused on critical unmet needs in oncology.

Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and treatments to prevent cancer.

Therapeutics

CAR-T

Anixa is developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Treatments

Breast Cancer Treatment

The company is developing a revolutionary treatment technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.

Ovarian Cancer Treatment

Using a similar mechanism of action as our breast cancer treatment technology, the company is developing a treatment to prevent the occurrence of ovarian cancer.

Today's ANIX Focus: Pre-Clinical Studies

Treatment Prevents Breast Cancer
image

Phase 1 Trial - Conducted by Cleveland Clinic, fund-ed by U.S. Department of Defense (DOD)

An open-label Phase 1 dose-escalation trial

Design: Participants will receive three treatments, each two weeks apart, and will be closely monitored for side effects and immune response

Phase 1a (in progress):

  • 18-24 Patients who have been treated for TNBC
  • Safety will be monitored
  • Immune Response will be monitored
  • Maximum Tolerated Dose (“MTD”) determined

Phase 1b (enrollment open):

  • Healthy women w/mutations
  • Chosen to undergo prophylactic mastectomy
  • Treatment before surgery and evaluate immune response and resected tissue
  • Unique opp. to garner supplemental data after studying breast tissue to determine if T cells are surveilling the tissue without any visible cancer tumors

Phase 1c (enrollment open):

  • Additional cohort combining treatment with Keytruda
  • Patients treated for TNBC
  • Combine Keytruda w/ treatment to evaluate if there is synergy

Breast Cancer Treatment: A Significant Market Opp.

Successive to appropriate clinical trials, a prophylactic (preventative) treatments may be eventually administered to the total eligible population.

Multi-Bn Dollar Market opp.
image

1) National Cancer Institute

If this treatment works as the company hopes and expects, every woman in the world may be eligible!

Anixa's Product Pipeline
image

Sources: Company Website. Company Presentation.

-----

Though that fills you in on the incredible company moves that ANIX is up to currently, it doesn't get to the heart of what we need to focus on right this second.

*Here Are The Most Pressing Potential Catalysts ANIX Is Working With...

#1. Bullish Technical Indicators (At Least 10 Triggered This Moment).

At close on Friday, Barchart was reporting ANIX to have a multitude of bullish technical indicators across the short, medium, and long term.

Here's a quick list:

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 100 Day MACD Oscillator
  • 50 - 150 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average

Not only those, but Barchart's composite "Trend Seeker" indicator is triggered, too.

#2. Game-Changing News Comes In The Form Of Positive Phase 1 Study Data.
image

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences stated: "The data from our Phase 1 trial to date has exceeded our expectations, and we are pleased with our progress. This treatment is designed to direct the immune system to destroy TNBC cancer cells through a mechanism that has never previously been utilized for cancer treatment development."

#3. Analyst Targets Suggest Triple-Digit Upside Potential From Current Levels.

Last, but no least, at least 2 different analysts have painted rosy targets on ANIX. Take a look at what MarketBeat has to share:
image

From Friday's closing valuation, these two targets represent over a 100+% potential upside!

Could it be time to stop sleeping on Anixa Biosciences, Inc. (ANIX)?

Time is officially ticking to get ANIX on radar now. When updates pop up, I'll have them out to you quickly this week.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
image
image